Today we’re excited to announce our official launch! A big thank you to Katherine Lewin and the great folks at Endpoints News for sharing our story. endpts.com/priming-therap…

Targeted therapies are incredibly effective in some instances but can fail in others because cancer is heterogeneous. So we asked ourselves: what if we made cancer cells easier for targeted therapies to eliminate? businesswire.com/news/home/2022…

A huge thank you to Josh Kopelman and the First Round team, Builders VC, Kevin Patrick Mahaffey, Matthew De Silva, Bioverge, and many others. Your support and guidance have been key in helping us get here—and we’re just getting started! businesswire.com/news/home/2022…

At Eigen, we’re tackling tumor heterogeneity by utilizing our platform to design combination therapies. Click here to learn more about our mission and team. eigentx.com

Eigen's CSO Kathryn, Senior Scientist Anu, and CTO Kamran are at #ASH2022! If you'd like to hear more about priming therapies, reach out to Kamran Ali. (his DMs are open) or fill out the form at the bottom of eigentx.com.

This #RareDiseaseWeek, we’re proud to celebrate our friends at @eigenTx + their work revolutionizing #cancertreatments. Their innovative platform is enhancing targeted therapies, offering new hope for rare disease patients. Learn about their work here: hubs.ly/Q038nJh10